NCT06252675 2026-04-20
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
University of California, San Francisco
Phase 2 Recruiting
University of California, San Francisco
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center